Pay in 4 interest-free payments of $6.12 Learn more
Ships within 48 hours · Estimated delivery Oct 10 - Oct 15
The development of GLP-1 receptor agonists for type 2 diabetes was contextualised within the broader research landscape, including orally bioavailable agonists, allosteric modulators, and unimolecular multi-agonists all of which use the native GLP-1 receptor as their primary target
The court also heard that the iDexis products had not been tested or approved by the South African Health Products Regulatory Authority (SAHPRA), while the source of the active ingredient had not been disclosed publicly
However, this is still an area being researched, with one study suggesting the improved glucose control remained after treatment for participants who took semaglutide for 68 weeks
Curr Opin Behav Sci (2017) 13:349
The safety profile is favorable, with common side effects including mild to moderate gastrointestinal issues like nausea and diarrhea, and a low rate of discontinuation due to adverse events
